CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 2, 2017--
Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at
the Canaccord Genuity 37th Annual Growth Conference in
Boston, MA on Wednesday, August 9 at 1:00 p.m. ET.
A live audio webcast of the presentation will be available under the
“Investors and Media” section of Seres’ website. A replay of the
presentation will become available approximately one hour after the
event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the natural state of bacterial diversity and function is
imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough and
Orphan Drug designations from the U.S. Food and Drug Administration and
is in Phase 3 development for multiply recurrent C. difficile
infection. Seres’ clinical candidate SER-287 is being evaluated in a
Phase 1b study in patients with mild-to-moderate ulcerative colitis.
Seres is also developing SER-262, the first ever synthetic microbiome
therapeutic candidate, in a Phase 1b study in patients with primary C.
difficile infection. For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170802005192/en/
Source: Seres Therapeutics, Inc.
IR or PR Contact:
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor
Relations and Corporate Communications